Morgan Stanley Sees Favorable GW Pharma (GWPH) Entry Point Ahead of Second LGS Trial Data
- Asia stocks bounce as soaring dollar pauses
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Dollar rally stalls after rare FX warning from finance chiefs
- Oil stabilises after sharp drop on demand concerns, easing of Middle East tension
- Netflix's subscribers, TSMC, Tesla upside - what's moving markets
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
GW Pharma (GWPH) PT Raised to $182 at Cantor Fitzgerald Following Successful Second LGS Trial
September 26, 2016 9:48 AM EDTCantor Fitzgerald analyst Elemer Piros raised his price target on Buy-rated GW Pharma (NASDAQ: GWPH) to $182.00 (from $165.00) after the company reported a second successful pivotal trial in Lennox-Gastaut syndromes (LGS).
Piros commented, "The second LGS trial was in most respects a... More
GW Pharma (GWPH) Gains ~13% on Positive Epidiolex Data in LGS
September 26, 2016 7:55 AM EDTGW Pharma (NASDAQ: GWPH) shares are trading up 12.9% after the company announced positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
... More